Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago CAR-T

Revolutionizing Medicine: CAR-T Therapy Beyond Cancer

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🔬 Over the past decade, CAR-T cell therapy has transformed the field of oncology, successfully treating previously incurable blood cancers. While CAR-T therapy gained fame for its success in cancer treatment, the roots of this groundbreaking principle trace back nearly 30 years—initially exploring T cell therapy for HIV/AIDS. Although the early attempts didn’t succeed in treating HIV/AIDS, they demonstrated the enduring potential of engineered T cells in immunocompromised patients.

🌟 CAR-T therapy, or Chimeric Antigen Receptor T-cell Immunotherapy, essentially involves reengineering a patient’s immune T cells outside the body to recognize antigens on the surface of tumor cells. These modified cells are then reintroduced into the patient, effectively identifying and eliminating cancer cells. Scientists have been tirelessly working to extend CAR-T therapy beyond blood cancers to various other types.

💡 Moreover, research from both clinical and preclinical studies indicates that CAR-T therapy holds great promise beyond cancer treatment. It shows potential applications in autoimmune diseases, chronic infections, heart diseases, aging-related conditions, and more.

🌐 In recent years, scientists have focused on applying CAR-T therapy to solid tumors, exploring its potential in cancer types beyond blood-related malignancies. Early research results suggest that the next frontier for CAR-T therapy may extend to various fields outside cancer, including autoimmune diseases (systemic lupus erythematosus, pemphigus vulgaris, multiple sclerosis, type 1 diabetes, asthma), fibrotic diseases (fibrosis in the heart, liver, lungs, and kidneys), aging-related conditions (liver fibrosis, solid tumors, atherosclerosis, natural aging), and infectious diseases (HIV/AIDS, hepatitis B and C, pulmonary tuberculosis).

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

#immunotherapyrevolution #CARTTherapy #MedicalInnovation #BeyondCancer #ImmunotherapyRevolution #CART #cancer #tumor #cancertreatment #tcell

9 months ago CAR-T

China Leading Global Advances in Breast Cancer Immunotherapy

🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer

Breast Cancer

Since 2020, breast cancer has surpassed lung cancer, becoming the most common cancer globally with approximately 2.3 million new cases and 680,000 deaths annually. Despite improvements in traditional treatments like surgery, chemotherapy, and radiation, the mortality rate remains high. China’s Chimeric Antigen Receptor (CAR) immunotherapy is making significant strides, spearheading innovation in breast cancer treatment. 🇨🇳💪

Recent studies indicate substantial breakthroughs in CAR-T therapy, as well as CAR-NK cells and CAR macrophages for breast cancer treatment. The application of combination therapies further enhances the cytotoxicity of CAR-based cell therapies against breast cancer cells, bringing new hope to patients. 🚀

China is at the forefront of global clinical research on CAR, with 16 clinical trials focused on CAR-T or CAR-NK cell therapies currently underway. Particularly noteworthy is the research at the People’s Liberation Army General Hospital, where CAR-T cells targeting CD133 are employed to treat refractory advanced malignant tumors, including breast cancer. This approach has demonstrated excellent anti-tumor activity and manageable safety in patients previously treated for advanced hepatocellular carcinoma and cholangiocarcinoma. 🏥✨

On another front, the clinical study at Sun Yat-sen Memorial Hospital, Zhongshan University, is equally intriguing. They are exploring PD-1 knockout CAR-T cells targeting MUC1 for treating late-stage breast cancer patients. This trial is a dose-escalation exploratory study, and researchers anticipate its results to pave the way for future treatments. 🧪🔍

China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏

#ImmunotherapyAdvancements #BreastCancerResearch

9 months ago CAR-T

The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.

The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.🌞🌞

🥰Surviving Against the Odds: A Chinese Doctor’s Journey with Liver Tumor🥰

Zou began his career in 1989 and has dedicated 30 years as an obstetrician-gynecologist, tirelessly working on the frontline of clinical care.

⭐️”One afternoon, I felt excruciating pain in my right shoulder while sitting in the office. It turned out I had three massive tumors on my liver. At that moment, I had no idea that my life had entered a countdown,” recalls Dr. Zou.⭐️

⭐️”Dr. Zou is in the advanced stage of liver cancer, with metastasis to the lungs,” urgently declared Prof.Shi as he convened a team of experts to consult on Dr. Zou’s condition.⭐️

⭐️ “With conventional treatment, the survival period is typically 3-6 months. Even with surgery, there’s no hope,” stated Prof.Shi.⭐️ Dr. Zou, a doctor himself, continued to ponder work matters, but colleagues and loved ones were tirelessly searching for any possible cure.

⭐️”Prof.Shi mentioned this immunotherapy, an antibody treatment,” said Dr. Zou’s wife.⭐️

Antibody therapy, specifically Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T), is a novel precision-targeted treatment for tumors. Using genetic engineering, T-cells are activated and equipped with a guided navigation device called CAR (Chimeric Antigen Receptor), transforming ordinary warriors into super soldiers known as CAR-T cells. These cells specifically recognize and efficiently eliminate tumor cells, achieving the goal of treating malignant tumors.

Fortunately, Dr. Zou’s health indicators perfectly matched the criteria for CAR-T therapy, providing him with a chance to defy death.

⭐️”In the early stages, I needed treatment every two weeks. Finally, after five or six sessions, my cancer cells started degenerating and liquefying. By now, the last and originally largest tumor has significantly liquefied and been absorbed,” Dr. Zou said.⭐️

⭐️”A miracle happened. We have taken a significant step in overcoming liver cancer in humans,” Prof.Shi added.⭐️

As the treatment gradually took effect, Dr. Zou’s health improved, allowing him to resume his daily work. After completing the treatment cycle, Dr. Zou once again donned the white coat, transitioning from patient to doctor.

In his heart, a stronger belief in the sincerity towards the medical profession and the health of patients emerged.

#SurvivorStories #MedicalMiracle #Inspiration #CancerSurvivor #CARTTherapy #AgainstAllOdds #HealthJourney #BelieveInMiracles #advancedmedicineinchina #chinesemedicine

10 months ago CAR-T

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors

At this year’s ASH conference, Professor Huang He, the director of the First Affiliated Hospital of Zhejiang University School of Medicine, presented a significant study on CAR-T cell therapy for B-ALL, marking a groundbreaking stride in the treatment of malignant hematologic system tumors.

This study, targeting newly diagnosed adult Ph-positive acute lymphoblastic leukemia, investigated the combined treatment of dasatinib and CAR-T cell therapy as a frontline therapy for initial patients. The integration of CAR-T cell therapy with tyrosine kinase inhibitors (TKI) aimed to enhance treatment effectiveness.

The study revealed promising outcomes: among 18 patients, the complete molecular remission rate after CD19 CAR-T cell therapy reached 72.2%. Among these patients, subsequent treatment with CD22 CAR-T cells achieved a complete molecular remission rate of 76.9%. At a median follow-up of 13.5 months post CAR-T cell therapy, 16 patients maintained complete hematological remission, while 14 patients sustained complete molecular remission without undergoing allogeneic transplantation. Notably, no CRS (cytokine release syndrome) ≥ Grade 3 or ICANS (immune effector cell-associated neurotoxicity syndrome) occurred during CAR-T cell therapy.

Professor Huang He’s team’s groundbreaking research presented at the ASH conference signifies a leap forward in the treatment of blood-related cancers, signaling a more efficient and accessible era. These findings instill hope for refining treatment strategies and potentially making a significant impact in the field of hematologic oncology.

Beyond the groundbreaking progress in CAR-T cell therapy combined with TKI, the team showcased seven oral presentations and 26 poster exhibitions. These studies encompassed fundamental research on blood disorders, leukemia pathogenesis, acute lymphoblastic leukemia, acute myeloid leukemia, lymphoma, myeloma, hematopoietic stem cell transplantation, and cellular immunotherapy, all crucial for enhancing clinical practices.

We eagerly anticipate further groundbreaking strides by Chinese research teams in cancer treatment studies, anticipating the transformative impact of these research findings in the future.

#ASHAnnualMeeting #HematologyResearch #CARTCellTherapy #StemCellTransplantation #BloodCancer #ClinicalInnovation #OncologyAdvancements #Cancertherapy #MedicalResearch #ASH #CART #CARTTherapy #CARTCell #TKI #tyrosinekinaseinhibitors

10 months ago CAR-T

Chinese Research: Hopes of CAR-T in Second-Line Treatment of LBCL（Lymphoma）

Diffuse Large B-cell Lymphoma （LBCL）is a heterogeneous malignant tumor of the blood system, with approximately 40% of LBCL patients experiencing relapse or developing resistance after first-line treatment, progressing to relapsed/refractory large B-cell lymphoma (R/R LBCL). In recent years, chimeric antigen receptor T-cell therapy targeting CD19 (CAR-T) has made significant breakthroughs in treating relapsed or refractory B-cell non-Hodgkin lymphoma.

At the 65th American Society of Hematology (ASH) Annual Meeting held from December 9th to 12th this year in the Eastern United States, important real-world evidence of CAR-T cell therapy as a second-line standard treatment for R/R LBCL was presented in the form of a poster (ASH Abstract #4876), providing crucial evidence-based medicine for the clinical application of CAR-T.

CAR-T Cell Therapy as Second-Line Treatment for R/R LBCL: Real-World

Evidence Among 110 patients receiving CAR-T infusion, the overall response rate (ORR) was 82.7%, and the complete response (CR) rate was 61.8%. Median progression-free survival (PFS) and overall survival (OS) were not reached. Estimated 6-month PFS and OS rates were 64.1% (95% CI, 52.8%-73.4%) and 84.4% (95% CI, 73.8%-90.9%), respectively.

The advent of CAR-T cell therapy has brought hope of cure for R/R LBCL patients. Based on its critical research and outstanding real-world application data, CAR-T cell therapy has gained recommendations from authoritative guidelines at home and abroad, and has become a crucial choice for second-line treatment in R/R LBCL patients.

#CARTCellTherapy #CancerTreatment #ScienceInnovation #GeneticMedicine #TumorTreatment #HealthcareTech #MedicalScience #CancerAwareness #PatientCare #FutureOfMedicine #CART #LBCL #Lymphoma #bloodcancer

10 months ago CAR-T

A significant breakthrough in Chinese solid tumor CAR-T therapy, resulting in complete remission for pancreatic cancer patients.

Chinese pharmaceutical company SciCoMed announced a significant breakthrough in treating metastatic pancreatic cancer with its independently developed CAR-T cell therapy targeting Claudin18.2, known as CT041. Pancreatic cancer, often termed the “king of cancers,” presents a significant challenge with low survival rates. However, CT041’s two representative cases have garnered attention: two patients with refractory pancreatic cancer, who failed multiple lines of treatment, received CT041 therapy. The results showcased a substantial reduction in tumor lesions and, in some cases, complete disappearance, offering a glimmer of hope for pancreatic cancer patients.

In the case of a 58-year-old female patient, lung metastases significantly decreased post CT041 treatment. Similarly, a 75-year-old female patient achieved complete remission by the fourth week post-treatment, maintaining remission to date. These successful cases validate the remarkable efficacy of CT041 for refractory pancreatic cancer, sparking interest and anticipation among international experts.

Moreover, CT041 has garnered recognition for its efficacy in the field of digestive system tumors. As the world’s first CAR-T cell therapy targeting Claudin18.2, it demonstrates promising prospects in treating digestive system tumors. Research data illustrates that among 37 patients, 83.3% experienced tumor regression, with an objective response rate of 48.6%. Additionally, CT041 displayed significant effectiveness in late-stage gastric and pancreatic cancer patients, offering hope for future treatments.

The rapid development of CAR-T therapy in China involves over 20 companies contributing significantly. CT041’s success signifies China’s progress toward becoming a global leader in CAR-T therapy. Moving forward, scientists will continue efforts to enhance efficacy and reduce side effects, providing a ray of hope for more late-stage cancer patients.

#CARTTherapy #CancerTreatment #Immunotherap #CT041 #PancreaticCancer #CART #PancreaticCancer #MedicalBreakthrough #SciCoMed #TumorTreatment #ClinicalResearch #HealthInnovation

Menu

Tags Archives: Tumor Treatment

Revolutionizing Medicine: CAR-T Therapy Beyond Cancer